img 614-636-4850
  • Follow us:

LEADERSHIP TEAM
KEY ADVISORS
BOARD OF DIRECTORS
SEC FILINGS




Extract Value from Natural and Chemically Modified Compounds


Pre-clinical portfolio of microbiome-derived immune-modulating peptides and other small molecules with exclusive technologies and the scientific expertise for discovering, expanding and advancing a valuable IO/I pipeline.

Primary Strategy:

  • • Deep dive into metabolome
    • • Concentration of minor metabolites
    • • Fractionanation to simplified pools for testing
    • • High rate of structured novelty
    • • Priority driven by biological activity (IP created)
    • • Potential to go directly to the organism

    Derivative strategy:

    • • Modify major metabolites
    • • Novel chemistry creates IP positions
    • • Abundant by-product compounds
    • • One-step chemistry transforms ADME properties
    • • Available for broad screening as pure compounds
    • • Synthetic GMP (IP creates)

    Two-prong strategy to explore pharmaceutical potential





Unprecedented Bias-Free Access to the Microbiome
that is Relevant to Human Health





Combining Novel Chemistry from the
Microbiome with Deep Analytics






Pin It on Pinterest